Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Study for the Treatment of Children and Adolescents With Newly Diagnosed Low Risk Hodgkin Disease

Next Previous
X
Search
Trial Profile

A Phase III Study for the Treatment of Children and Adolescents With Newly Diagnosed Low Risk Hodgkin Disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Cyclophosphamide (Primary) ; Cytarabine (Primary) ; Dexamethasone (Primary) ; Doxorubicin (Primary) ; Etoposide phosphate (Primary) ; Filgrastim (Primary) ; Filgrastim (Primary) ; Filgrastim (Primary) ; Ifosfamide (Primary) ; Prednisone (Primary) ; Vincristine (Primary) ; Vinorelbine (Primary)
  • Indications Hodgkin's disease
  • Focus Therapeutic Use

    • Most Recent Events

    • 28 Jun 2022 Results investigating the impact of PET response after 1 cycle (PET1) and IFRT on outcomes and relapse pattern, published in the Blood
    • 24 Aug 2012 Status changed from suspended to completed as reported by ClinicalTrials.gov.
    • 03 Jul 2009 Additional lead trial investigators identified as reported by New Jersey Cancer Trial Connect record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top